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Introduction
The hygiene hypothesis has been raised for more than 2 
decades.1 Although conflicting results have been reported, it is 
generally accepted that some infections, especially intracellular 
bacterial and parasitic infections, may have a negative impact 
on the development of allergic and autoimmune diseases.2-4 The 
mechanism behind the hygiene hypothesis is believed to be related 
to immune deviation and/or immune regulation. Indeed, some 
bacterial infections have been found to alter an allergen-driven T 
helper 2 (Th2) -cell response to a T helper 1 (Th1)-dominated-
cell response. The reduction of allergic reactions and Th2-cell 
responses was associated with enhanced Th1-cell response.5,6
Cow’s milk allergy (CMA), an immunological mediated reac-
tion to cow’s milk proteins, is one of the most prevalent human 
food allergies, particularly in infants and young children.7 It is 
known that allergic disorders are mediated by T lymphocytes 
secreting  Th2 cytokines, resulting in high levels of serum IgE 
with the risk of life-threatening anaphylaxis after a repeated expo-
sure to the allergen. One of the corrective strategies explored to 
downregulate the Th2 effector immune response is the induction 
of a specific Th1 counter-acting immune response that controls 
the adaptive immunity and the clinical response to the offending 
allergen.8,9 So, a lower exposition to TLR ligands plus an increase 
exposition to allergens affect the immunologic homeostasis and 
influence the development of allergy. Many immunomodulatory 
strategies that use pro-Th1 adjuvants have been based on this 
hypothesis.10
The outer membrane protein of 16 kDa from B. abortus 
(U-Omp16) is a new Brucella pathogen associated molecular 
pattern (PAMP) that activates dendritic cells (DCs) in vivo and 
has self-adjuvanting properties when administered by the oral or 
intraperitoneal route inducing protection against B. abortus chal-
lenge. We found that these responses were TLR4 mediated.11 We 
also demonstrated that the nasal co-administration of U-Omp16 
with the model antigen (Ag) ovalbumin (OVA) induced OVA-
specific systemic IgG and Th1 immune responses. In addition, 
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Food allergies are increasingly common disorders and no therapeutic strategies are yet approved. The unlipidated 
Omp16 (U-Omp16) is the outer membrane protein of 16 kDa from B. abortus and possesses a mucosal adjuvant property. 
In this study, we aimed to examine the U-Omp16 capacity to abrogate an allergen-specific Th2 immune response when 
it is administered as an oral adjuvant in a mouse model of food allergy.
Balb/c mice were sensitized with cholera toxin and cow’s milk proteins (cMP) by gavage and simultaneously treated 
with U-Omp16 and cMP. Oral challenge with cMP was performed to evaluate the allergic status of mice. symptoms, local 
(small bowel cytokine and transcription factor gene expression) and systemic (specific isotypes and spleen cell-secreted 
cytokines) parameters, and skin tests were done to evaluate the immune response.
We found that the oral administration of U-Omp16 with cMP during sensitization dampened the allergic symptoms, 
with negativization of immediate skin test and increased skin DTh response. serum specific Ige and IL-5 were inhibited 
and a Th1 response was promoted (specific IgG2a antibodies and cMP-induced IFN-γ secretion). We found at the muco-
sal site an inhibition of the gene expression corresponding to IL-13 and Gata-3, with an induction of IFN-γ and T-bet.
These results indicated that the oral administration of U-Omp16 significantly controlled the allergic response in sen-
sitized mice with a shift of the balance of Th1- and Th2-T cells toward Th1 predominance. These findings suggest that 
U-Omp16 may be useful as a Th1-directing adjuvant in an oral vaccine.
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Figure 1.  For figure legend see page 2017.
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the utility of U-Omp16 was also assessed in a mouse model of 
food allergy. The intranasal administration of U-Omp16 dur-
ing the sensitization ameliorated the hypersensitivity response 
of sensitized mice upon oral exposure to cow’s milk proteins 
(CMP), reduced the clinical signs, decreased anti-CMP IgE 
serum antibodies and modulated the Th2 response in favor of 
Th1 immunity.12
Among different mucosal routes, oral delivery is the most 
easy and acceptable way to administer a formulation, especially 
in children. Thus, the purpose of this study was to examine the 
U-Omp16 capacity to downregulate an allergen-specific Th2 
immune response when it is administered as an adjuvant through 
the oral route. These findings may provide a novel therapeutic 
approach for allergic diseases.
Results
The oral administration of U-Omp16 with CMP controls 
the induction of allergy
To study the adjuvant capacity of U-Omp16 in an oral for-
mulation, mice were intragastrically (i.g.) administered with 
U-Omp16 during the sensitization phase and the induction of an 
allergic reaction was studied. As control, a group of mice received 
CpG (Th1 adjuvant) with CMP by gavage, another group of 
mice received only CMP (no sensitization) and OVA was used 
as a non-related antigen (Fig. 1A shows a schematic representa-
tion of the experimental protocol). An oral challenge following 
the sensitization phase was performed to evidence the induction 
of hypersensitivity reactions immediately after the exposure to 
the allergen. The clinical signs were scored (Fig. 1B) and we 
evidenced that treated animals (Sens/Omp16 and Sens/CpG) 
showed significant lower clinical scores compared with sensitized 
animals exposed to CMP (Sens/PBS) (average score 0.6 for Sens/
CpG, 1.0 for Sens/Omp16 and 3.0 for Sens/PBS; P < 0.001), 
which suggests that the allergic sensitization was ameliorated 
with the use of these adjuvants. No symptoms were observed in 
control animals that received only CMP or in animals that were 
sensitized to CMP and then challenged with OVA (score 0).
We indirectly demonstrated that this suppressed reaction 
could be linked to a lower presence of membrane-bound IgE to 
mast cells through the cutaneous test. Figure 1C shows that an 
immediate extravasation of the blue dye was only observed in 
sensitized mice that were subcutaneously injected with CMP in 
vehicle. No increase in vascular permeability was observed in 
mice treated with U-Omp16 or CpG plus CMP or in control 
animals that received only CMP and were injected with CMP. 
Milk-sensitized mice that were injected with OVA showed no 
extravasation of the dye. These findings indirectly indicate that 
IgE-sensitization of skin mast cells is lower in U-Omp16- or 
CpG-treated animals compared with cells from sensitized mice. 
This situation may be extended to tissue mast cells and circulating 
basophils and reflects the absence of immediate reaction follow-
ing the oral challenge with the allergen. To further investigate if 
U-Omp16 promoted a specific Th1-mediated immune response, 
a DTH response was examined. We found a statistically signifi-
cant increased DTH reaction in mice that received U-Omp16 as 
adjuvant plus the allergen (average footpath thickness = 0.24), 
compared with control or sensitized animals (average footpath 
thickness = 0.03 or 0.07, respectively) (Fig. 1D).
The intragastric administration of U-Omp16 promotes a 
Th1-immune response
To analyze the specific immune response induced by the 
adjuvants, the production of the different CMP-specific immu-
noglobulins was monitored during the protocol. Specific IgE 
antibodies were significantly increased in the sensitized animals 
after the oral challenge, whereas low levels of specific IgE was 
detected in the animals that received only CMP. Besides, we 
observed that the oral administration of U-Omp16 plus CMP 
reduced the CMP-specific IgE levels as much as 55%, similar to 
43% achieved with the CpG treatment (Fig. 2A), whereas levels 
of CMP-specific IgG2a increased as much as 68% with Omp16/
CMP treatment, and 80% with CpG/CMP treatment (Fig. 2B). 
This isotype remained unchanged in control mice, which sug-
gests that it was promoted with the intragastric administration of 
U-Omp16 or CpG.
To confirm the pro-Th1 oral adjuvant properties of U-Omp16, 
the cytokine production of Ag-stimulated spleen cells was stud-
ied. As depicted in Figure 3A, we found that IL-5 was highly 
secreted by cells from sensitized animals (85 ± 20 pg/mL), while 
IFN-γ was very low (15 ± 4.1 pg/mL). The co-administration of 
CMP with U-Omp16 or CpG induced the production of IFN-γ 
in splenocytes (45 ± 4.8 pg/mL for U-Omp16/CMP and 100 ± 
21 pg/mL for CpG/CMP) with a reduced secretion of IL-5 (10 ± 
3.2 pg/mL for U-Omp16/CMP) (Fig. 3A). Importantly, CD4+ T 
cells were found as being a relevant source of IFN-γ in U-Omp16 
treated mice compared with CMP treated mice (7.08 ± 1.10% 
sensitized/U-Omp16 vs 1.26 ± 1.12% sensitized/PBS, P < 0.05) 
(Fig. 3B).
To further evaluate the intestinal induction of a Th1-immune 
response, the whole-tissue gene expression of cytokines and tran-
scriptional factors was analyzed as an indirect marker of the local 
Figure  1. experimental design and in vivo assays. (A) schematic overview of the experimental design for the food allergy mouse model in BaLB/c 
mice. (B) hypersensitivity scores of sensitized mice 30 min after last challenge with cMP. each point represents an individual mouse. Mice were treated 
with PBs+cMP (control) or cpG+cMP (sens/cpG) as controls, or U-Omp16+cMP (sens/Omp16), and intragastric challenge was performed with cMP or 
OVa, as control. Mean and standard deviation are indicated. Data are representative of 2 independent experiments (n/group = 5). (C) cutaneous test 
performed before the oral challenge showing the blue color corresponding to extravasation of blue evans in a positive reaction. cMP, OVa, or PBs were 
inoculated in mice’s ears and blue evans, in the tail vein. (D) Delayed-type hypersensitivity (DTh) response to cMP was assayed 3 wk after the last boost 
to evaluate the cellular immune response in vivo. Twenty μg of cMP were injected into one footpad, and saline was injected into the contra lateral foot-
pad, as a negative control. The thickness of both footpads was measured 48 h later. Results are shown as mean increment in the hind footpad between 
right and left foot ± seM at 48 h for each group (n/group = 5). significant difference from cMP alone treated group is indicated (*P < 0.05). Results are 
representative of 2 independent experiments.
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immune response induction. The data output showed in Figure 4 
is expressed as a fold-difference expressed as mean ± SEM of indi-
vidual gene expression ratio of treated to control animals. We 
found increased transcript levels corresponding to IL-13, IL-5, 
and Gata-3 genes in the jejunum of sensitized mice (fold increase 
of 16.2 ± 5.1 for IL-13, 2.1 ± 1.1 for IL-5, and 5.8 ± 0.3 for 
Gata-3, compared with treated animals which showed upregu-
lated gene expression of IFN-γ and T-bet (4.7 ± 0.5 and 5.1 ± 
0.8 of fold increase, respectively) (Fig. 4A and B). Remarkably, 
U-Omp16-treated animals showed the highest transcript levels of 
these Th1 T-cell differentiation markers.
Overall these findings provide a strong evidence of the pro-
Th1 mucosal adjuvant properties of U-Omp16 that could control 
the IgE-mediated allergic reaction in sensitized mice.
Discussion
Mucosal vaccines have several advantages compared with 
systemic vaccines in terms of practicity in administration, 
safety, regulatory aspects, and production and purity. However, 
the development of mucosal adjuvants has been the most chal-
lenging point to overcome and is a crucial step when defining 
vaccine candidates. Although it has been demonstrated that 
mucosal vaccines contribute to stimulate protective immune 
responses against mucosal and non-mucosal infectious, and 
to control the aberrant immune response in inflammatory 
(allergy, autoimmunity)13,14 and non-inflammatory disorders 
(cancer),15 a few commercially available vaccines have been 
approved.16,17
Regarding food allergy there is an unmet clinical need for an 
effective therapy; thus development of therapeutic interventions 
is a research priority. Allergen immunotherapy is associated 
with a risk of anaphylaxis, and in the last decades, significant 
progress has been made for the management of allergic diseases. 
Studies are concentrated on long-term efficacy, safety due to 
local and systemic side effects, and the use of safe and effective 
adjuvants in human vaccines. Therefore promising antigen-spe-
cific therapies are based on the development of novel adjuvants 
and innovative methods for delivery, in combination with new 
routes of administration, that skew the immune response away 
from a Th2-mediated allergic response.
Figure 2. U-Omp16 when administered as an oral adjuvant for treatment induces a modulation of specific isotypes. Determination of cMP-specific 
serum (A) Ige, (B) IgG2a after the oral cMP sensitization and treatment; C) IgG1/IgG2a ratio. Data represents the mean ± seM from each group of 10 mice 
(***P < 0.001, **P < 0.01, *P < 0.05 vs cMP treated group). These results are representative of 2 independent experiments.
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Novel immunologic adjuvants based on pathogen-associated 
molecular patterns, such as TLR agonists, constitute relevant 
mucosal adjuvants, which have been successfully used in experi-
mental animal models and in clinical trials.18-21 In particular 
CpG-oligodeoxynucleotide (ODN)-containing formulations 
(TLR9 agonists), monophosporyl lipid A (TLR4 agonist), and 
flagellin (TLR5 agonist) have been widely investigated.18,19,22 In 
this work we have studied the properties of U-Omp16 as an oral 
adjuvant using an IgE-mediated mouse model of food allergy. 
Our findings indicate that U-Omp16 delivered by the oral route 
drives a Th1 immune response to co-delivered CMP, and abol-
ished the Th2-mediated IgE secretion that induced the allergic 
immune response in mice. This Brucella PAMP promoted the 
induction of CD4-producing IFN-γ cells that mediated the 
mucosal immunomodulatory effect observed. It has been previ-
ously demonstrated that this newly described PAMP activates 
Figure 3. Treatment with U-Omp16 stimulates the induction of cD4+ cMP-specific T cells that produce IFN-γ. (A) spleen cells were collected 24 h after 
the oral challenge and stimulated in vitro with 350 µg/mL of cMP for 72 h. Levels of IL-5 and IFN-γ in culture supernatants of spleen cells from sensitized 
and treated mice were determined by eLIsa. supernatants were analyzed in triplicate and IL-5/IFN-γ is also depicted. (B) spleen cells from sensitized 
and treated mice were incubated with brefeldin a for the last 4 h of culture, and then were stained with specific anti-cD4 (Pe) monoclonal antibody. 
subsequently, cells were fixed, permeabilized, and stained with an anti-IFN-γ (FITc) or isotype control (FITc) monoclonal antibodies. samples were 
analyzed by flow cytometry and data are expressed as mean values ± seM (*P < 0.05 vs cMP treated group). Results shown are representative of 2 inde-
pendent experiments.
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dendritic cells through binding to TLR4.11 These results, in 
accordance with our previous works,11,12 prompt us to propose 
the use U-Omp16 as a mucosal adjuvant to enhance or control 
an Ag-specific immune response. Of note, the immunomodula-
tory properties of U-Omp16 were comparable to CpG adminis-
tration. Several reports have described that the administration 
of the allergen with oligodeoxynucleotides containing unmethyl-
ated CpG motifs by subcutaneous, intraperitoneal, nasal, or oral 
administration shift the balance between Th1- and Th2- T cells 
toward a Th1 predominance, with the reduction of the allergic 
reaction in mice.23-27 Beeh et al. have conducted a randomized, 
double-blind, placebo-controlled clinical trial in patients with 
persistent allergic asthma requiring long-term treatment with 
inhaled corticosteroids (ICS). Patients received weekly subcuta-
neous injections of QbG10 (bacteriophage Qbeta-derived virus-
like particle with CpG-motif G10 inside), while ICS treatment 
was steeply withdrawn. In treated patients asthma improved and 
a considerable reduction of ICS was achieved. On the other hand, 
patients receiving placebo, the withdrawal of ICS led to a wors-
ening.20 The clinical efficacy of immunomodulatory agents con-
taining a CpG motif has also demonstrated by Klimek et al.28 in 
other atopic conditions.
In the food allergy mouse model here employed the cholera 
toxin was used as a pro-Th2 mucosal adjuvant. The immuno-
modulatory properties of this bacterial enterotoxin are not based 
on TLR binding. It binds via the B subunit to gangliosides pres-
ent in the cell membrane of nucleated cells (GM1) and promotes 
the synthesis of cytosol cyclic AMP. Due to severe unwanted side 
effects developed in vaccinated subjects29-32 this mucosal adjuvant 
has not been approved for human vaccines.
The aim of the most advanced novel allergen-specific immu-
notherapy is to interfere with the Th2 pro-allergic mechanisms, 
re-directing the immune response to a mixed Th1-Th2 response 
by the administration of small doses of allergens with or without 
adjuvants. Such an immunological response may be achieved by 
mimicking infections with natural pathogens. Therefore stimu-
lating TLRs that promote a Th1-T cell based immune response 
may be an attractive way to achieve this goal. To this end, we 
used the Brucella PAMP U-Omp16 that has proved to be effec-
tive as a pro-Th1 auto-adjuvant and intranasal adjuvant to con-
trol food allergy. In this work we succeeded in inducing the 
production of IFN-γ and a Th1-mediated immune response 
that halted the development of the allergic Th2-based reaction, 
using the recombinant U-Omp16 as an oral adjuvant. Of note, 
the use of this novel TLR agonist showed a significant impact in 
the inhibition of symptoms immediately following the exposure 
to the allergen in sensitized and treated mice. Concomitantly, 
the production of IgE was systemically suppressed, which was 
also reflected at the cellular level (negative skin test). In addi-
tion, the DTH test was higher in treated mice compared with 
sensitized and placebo treated animals indicating the presence 
of specific Th1 cells. In concordance, IFN-γ and IgG2a were 
raised indicating a Th1-mediated immune response induced 
with the oral administration of U-Omp16 and CpG. We could 
also evidence that Th2 cells were controlled at the mucosal site 
with a reduction of Gata-3 gene expression and induction of 
T-bet. Overall these findings clearly indicate that U-Omp16 
significantly contributes to the control of the allergic immune 
response in an IgE-mediated mouse model of food allergy. 
Further research with IFN-γ neutralizing antibodies or in 
IFN-γ null mice is required to confirm the central role of this 
Th1 cytokine in the suppression of the allergic reaction using 
oral U-Omp16.
In conclusion, we have studied the anti-allergic properties 
of the bacterial adjuvant U-Omp16 through the oral route, and 
we demonstrated that the intestinal IgE-mediated allergic sen-
sitization was dampened. Although further research is manda-
tory to confirm the IFN-γ-based immunomodulatory effect of 
U-Omp16, this approach may show promise for safe oral use of 
this novel mucosal adjuvant for the treatment of food allergy.
Figure 4. U-Omp16 induces a modulation of cytokine and transcription factor gene expression at the mucosal site. (A) mRNa expression for cytokines 
(IL-5, IL-13, and IFN-γ) and (B) transcription factors (T-bet and Gata-3) was quantified 24 h after oral challenge in jejunum segments. β-actin was assessed 
as a housekeeping gene for standardization in each sample and fold increased was calculated by comparing sensitized and control mice gene expres-
sion. Data represents the mean ± seM from each group and are representative of 2 independent experiments (***P < 0.001, **P < 0.01, *P < 0.05 vs cMP 
treated group).
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Materials and Methods
Mice
Male 8-wk-old specific pathogen-free BALB/c mice were pur-
chased from the School of Animal Science at the University of 
La Plata. Mice were housed in appropriate conventional animal 
care facilities and handled according to international guidelines 
required for animal experiments. Animals were grouped in 5 
mice per condition and experiments were repeated at least twice.
All the experimental protocols of this study were conducted 
in strict agreement with the international ethical standards for 
animal experimentation (Helsinki Declaration and its amend-
ments, Amsterdam Protocol of welfare and animal protection 
and National Institutes of Health, USA NIH, guidelines: Guide 
for the Care and Use of Laboratory Animals). All experimental 
procedures were reviewed and approved by the local Institutional 
Animal Care and Use Committee at the School of Animal 
Science (University of La Plata).
Antigens and adjuvants
CMP extract and the recombinant U-Omp16 were obtained 
as previously described.33,12 Briefly, recombinant U-Omp16 was 
isolated from bacterial cytoplasm and then purified by affin-
ity chromatography with a Ni-NTA resin (Qiagen). Expression 
and purification of the recombinant protein was checked by 
SDS-PAGE followed by Coomasie Blue staining and to confirm 
the identity of the U-Omp16, western blot was performed and 
developed with anti–Omp16-specific mAb (data not shown). 
Protein concentration was determined by the bicinchoninic 
acid [2-(4-carboxyquinolin-2-yl)quinoline-4-carboxylic acid] 
assay with bovine seroalbumin as a standard (Pierce). Depletion 
of lipopolysaccharide (LPS) was performed with a Sepharose-
polymyxin B resine (Sigma-Aldrich). Endotoxin determina-
tion was performed with Limulus amoebocyte chromogenic 
assay (LONZA). Protein preparation contained less than 0.10 
endotoxin U/mg proteins. The CpG-ODNs contained 2 CpG 
motifs (ODN 1826) and were purchased from Invivogen. The 
complete sequence for CPG-ODNs is 5′-TCCATGACGT 
TCCTGACGTT-3′.
Sensitization and treatment of mice
Mice were sensitized as previously described.33 Briefly, mice 
received 6 weekly intragastric (i.g) doses of 20 mg of CMP 
administered as homogenized commercial non-fat dry milk, plus 
10 μg of cholera toxin (CT) (Sigma Aldrich) in a final volume of 
200 μL of bicarbonate buffer (sensitized mice). As control group 
naïve mice received 6 weekly i.g doses of 20 mg CMP with PBS. 
To modulate the allergic sensitization, mice received by gavage 
during the sensitization 4 µg CMP plus 100 µg U-Omp16 (Sens/
Omp16), 4 µg CMP plus 100 µg of CpG (Sens/CpG) as a posi-
tive treatment control, or 4 µg CMP in PBS as negative treatment 
control (Sens/PBS) twice a week. Ten days after the final boost 
mice were i.g challenged with 20 mg CMP and symptoms were 
immediately evaluated in a blinded fashion by 2 other research-
ers. Individual mice only received one treatment. Blood samples 
were collected during the whole protocol and sera were stored at 
–20 °C until use. The experimental design is shown in Figure 1A.
In vivo evaluation of the allergic reaction
Assessment of clinical signs
Symptoms were observed between 30 and 60 min after the 
oral challenge in a blinded fashion by 2 independent researchers. 
Clinical scores were assigned according to the following range: 
0 = no symptoms; 1 = scratching and rubbing around the nose 
and head; 2 = puffiness around the eyes and mouth, diarrhea, 
pilo- erection, reduced activity, and/or decreased activity with 
increase respiratory rate; 3 = wheezing, labored respiration, cya-
nosis around the mouth and the tail; 4 = no activity after prod-
ding, or tremor and convulsion; and 5 = death.
Cutaneous test
Mice were injected intradermically with 20 μg of CMP in 
20μL of sterile saline in one ear and saline alone in the other ear 
as negative control. Mice were also injected intravenously (tail 
vein) with 100 µL of 0.1% Evans blue dye (Anedra). The pres-
ence of blue color in the ear minutes after the injection was con-
sidered positive.
DTH test
Twenty-one days after the last boost the delayed-type hyper-
sensitivity (DTH) response was measured by determining the 
footpad swelling after a subcutaneous injection of 20 μg of CMP 
in 20 μL PBS into one hind footpad. As a negative control saline 
was similarly injected into the contra-lateral footpad. Footpad 
swelling was measured 48 h post injection with a digital microm-
eter with a minimum increment of 0.01 mm.
In vitro evaluation of the allergic reaction
Serum specific IgE detection
For the evaluation of specific IgE antibodies against CMP 
serum samples were tested by EAST as described before.33 
Briefly, cyanogen bromide-activated cellulose paper discs were 
coupled with CMP extracts containing 1.75 mg/mL of protein. 
Discs were blocked with ethanolamine, and incubated overnight 
at 4 °C with 50 µL of serum samples. IgE isotype was revealed 
using a biotinylated anti-mouse IgE monoclonal antibody (BD 
Pharmigen) at 1:1000 dilution during 5 h at 4 °C, followed with 
an alkaline phosphatase-streptavidin conjugate (Sigma-Aldrich) 
at 1:3000 dilution during 30 min at 37 °C. The enzymatic activ-
ity was revealed with p-nitrophenyl phosphate (Biochemika, 
Fluka) and stopped with 0.1 M EDTA. Optical density (OD) 
was measured at 405 nm.
Serum specific IgG1 and IgG2a detection
CMP-specific IgG1 and IgG2a antibodies were measured by 
ELISA as previously described.33 Briefly, Maxi Sorp ELISA plates 
(NUNC) were coated overnight at 4 °C with 1 μg/100 μL CMP 
in carbonate-bicarbonate buffer (pH 9.6). Coated plates were 
blocked with 5% equine serum in saline for 2 h at 37 °C and 
then incubated with sera (1/200) for 1 h at 37 °C. Bound anti-
gen-specific immunoglobulins were detected using a sheep anti-
mouse isotype-specific antibody (The Binding Site) (1/1000, 1 h 
at 37 °C), followed by incubation with a horseradish peroxidase-
conjugated goat anti-sheep antibody (Jackson Immunoresearch) 
(1/10 000, 1 h at 37 °C). The reaction was developed with 
o-phenylenediamine (Sigma-Aldrich), and stopped with 2 M 
H
2
SO
4
. OD was measured at 492 nm.
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Cytokine response of stimulated splenocytes analysis
Twenty-four hours after the oral challenge mice were killed 
and spleens were aseptically removed. Single cell suspensions 
were prepared in complete medium. Splenocytes (4 × 106 cells/
well) were cultured for 72 h at 37 °C in a humidified atmosphere 
containing 5% CO
2
 with complete medium alone (RPMI supple-
mented with 10% FBS, 10U/mL penicillin, and 10mg/mL strep-
tomycin) as control or in complete medium containing CMP 
(0.35 mg/mL) for CMP-specific cell stimulation. Supernatants 
were harvested and assayed for IL-5 and IFN-γ by ELISA using 
commercially available kits (Invitrogen) according to manufac-
turer’s instructions. For cytokine staining by flow cytometry, 
spleen cells from sensitized and treated mice were incubated 
with brefeldin A (BD Bioscience) for the last 4 h of culture, and 
then stained with specific anti-CD4 (PE) monoclonal Ab (BD 
Bioscience). Subsequently, cells were fixed, permeabilized, and 
stained with an anti-IFN-γ (FITC) or isotype control (FITC) 
monoclonal Abs (BD Bioscience). Sample acquisition was per-
formed with a FACScalibur cytometer using QuestProCell soft-
ware. The data were analyzed with the FlowJo software.
Mucosal gene expression analysis
The jejunum was aseptically removed from mice killed by 
cervical dislocation 24 h after oral challenge and mRNA was 
isolated using illustra RNAspin mini isolation kit according the 
manufacturer’s specifications (GE Healthcare). Peyer’s patches 
were discarded prior to tissue processing. Briefly, samples were 
homogenized in buffer lysis with β-mercaptoethanol, then 
lysates were filtrated to eliminate clumps or debris and the RNA 
was precipitated with ethanol. Suspensions were centrifuged 
for RNA binding to silica. Finally, DNase was added and after 
washing, RNA was eluted in water. The amount of the extracted 
RNA was determined by UV absorption with a spectrophotome-
ter and the optical density ratio of OD
280nm
/OD
260nm
 was used as 
a purity measure. Complementary DNA (cDNA) was obtained 
from 1 µg of RNA using M-MLV reverse transcriptase and 
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AGTCTTCTCT).
Statistical analysis
All statistical analysis and plotting were performed using 
GraphPad Prism 5 software. Data were displayed as mean ± 
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formed, whereas when more than 2 groups were conducted, the 
significance of the difference was determined using ANOVA test 
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to archive a normal distribution. A P value < 0.05 was considered 
as statistically significant.
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